Arcutis Biotherapeutics (ARQT) Current Leases (2019 - 2025)
Arcutis Biotherapeutics (ARQT) posted quarterly Current Leases of $842000.0 for Q1 2025, up 11.38% year-over-year from $756000.0 in Q1 2024, and up 2.68% quarter-over-quarter from $820000.0 in Q4 2024.
Arcutis Biotherapeutics (ARQT) Current Leases (2019 - 2025) Analysis & Trends
Arcutis Biotherapeutics' Current Leases history runs 7 years deep, the most recent figure standing at $842000.0 for Q1 2025.
- In Q1 2025, Current Leases rose 11.38% year-over-year to $842000.0; the TTM figure through Mar 2025 stood at $842000.0 (up 11.38% YoY), while the FY2024 annual figure was $820000.0, up 11.56% from the prior year.
- Current Leases for Q1 2025 stood at $842000.0, up from $820000.0 in the prior quarter.
- The five-year high for Current Leases was $842000.0 in Q1 2025, with the low at $106000.0 in Q2 2021.
- The 5-year median for Current Leases is $685500.0 (2023), against an average of $627750.0.
- The sharpest annual moves came in 2021 and 2025: Current Leases surged 856.25% in 2021, then grew 11.38% in 2025.
- Arcutis Biotherapeutics' Current Leases stood at $433000.0 in 2021, then jumped by 51.73% to $657000.0 in 2022, then advanced by 11.87% to $735000.0 in 2023, then grew by 11.56% to $820000.0 in 2024, then rose by 2.68% to $842000.0 in 2025.
- Business Quant data shows ARQT's Current Leases at $842000.0 in Q1 2025, $820000.0 in Q4 2024, and $798000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 11.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 16.75 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 21.95 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 2.24 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 45.93 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 842,000.00 |
| Dec 31, 2024 | 820,000.00 |
| Sep 30, 2024 | 798,000.00 |
| Jun 30, 2024 | 777,000.00 |
| Mar 31, 2024 | 756,000.00 |
| Dec 31, 2023 | 735,000.00 |
| Sep 30, 2023 | 715,000.00 |
| Jun 30, 2023 | 695,000.00 |
| Mar 31, 2023 | 676,000.00 |
| Dec 31, 2022 | 657,000.00 |
| Sep 30, 2022 | 639,000.00 |
| Jun 30, 2022 | 582,000.00 |
| Mar 31, 2022 | 507,000.00 |
| Dec 31, 2021 | 433,000.00 |
| Sep 30, 2021 | 306,000.00 |
| Jun 30, 2021 | 106,000.00 |
| Sep 30, 2020 | 32,000.00 |
| Jun 30, 2020 | 80,000.00 |
| Mar 31, 2020 | 182,000.00 |
| Dec 31, 2019 | 178,000.00 |